Antibacterial agent 318

Antibacterial agent 318 (compound 12f) inhibits the growth of E. faecalis, L. species, B. subtilis, S. aureus, E. coli, and S. marcescens with MIC values ranging from 1.56 to 6.25 μg/mL^[1].
Antibacterial agent 318 (1.56-12.48 μg/mL; 2.5-5 h) exhibits rapid bactericidal activity against E. faecalis, killing bacteria within 5 h at 1× MIC and 3.5 h at 8× MIC, with synergistic faster killing (2.5 h) when combined with Tetracycline (HY-A0107)^[1].
Antibacterial agent 318 (1.56-12.48 μg/mL) inhibits E. faecalis biofilm formation and auto-aggregation in a concentration-dependent manner, reducing formation by 83% at 8× MIC^[1].
Antibacterial agent 318 (1.56-12.48 μg/mL) reduces E. faecalis EPS content by 69.7% at 1× MIC and 74.4% at 8× MIC^[1].
Antibacterial agent 318 (30 μM) exhibits minimal cytotoxicity toward HEK293 cells, with viability above 87% at 30 μM^[1].
Antibacterial agent 318 (1.56 μg/mL) causes severe morphological damage to E. faecalis cells at 1× MIC, including ruptured cell walls and cytoplasmic leakage^[1].
Antibacterial agent 318 (1.56-12.48 μg/mL) can induce metabolic arrest in E. faecalis, induce E. faecalis to produce intracellular reactive oxygen species (ROS) in a concentration-dependent manner, and reduce GSH activity; it can also induce lipid peroxidation, increasing MDA levels up to 6-fold at a concentration of 8× MIC^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.